Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$47.44

 0.54 (1.13%)

High$47.94
Low$47.26
Volume68,605
Market Cap$6,741,979,319

07/28/16  10:07 a.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Reports Second Quarter 2016 Financial Results 07/26/16

Read more

Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS® (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 07/18/16

Read more

Events

2nd Quarter 2016 Financial Results07/26/16 4:30 p.m. ETView eventUBS Global Healthcare Conference05/24/16 10:30 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources